GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer

Mostrar otras versiones (1)

Inhibition of GSK-3 using small-molecule elraglusib has shown promising preclinical antitumor activity. Using in vitro systems, we found that elraglusib promotes immune cell-mediated tumor cell killing, enhances tumor cell pyroptosis, decreases tumor cell NF-κB-regulated survival protein expression,...

Descripción completa

Detalles Bibliográficos
Autores principales: Huntington, Kelsey E., Louie, Anna D., Srinivasan, Praveen R., Schorl, Christoph, Lu, Shaolei, Silverberg, David, Newhouse, Daniel, Wu, Zhijin, Zhou, Lanlan, Borden, Brittany A., Giles, Francis J., Dooner, Mark, Carneiro, Benedito A., El-Deiry, Wafik S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934544/
https://www.ncbi.nlm.nih.gov/pubmed/36798357
http://dx.doi.org/10.1101/2023.02.07.527499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934544/
https://www.ncbi.nlm.nih.gov/pubmed/36798357
http://dx.doi.org/10.1101/2023.02.07.527499

Ejemplares similares